Clinical Trial Update: Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating low-dose naltrexone for fatigue management in metastatic prostate cancer patients on androgen deprivation therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Naltrexone (Naltrexone)

Snippet

Sponsor: University of Arkansas | Conditions: Metastatic Prostate Cancer | Phase 2 | Status: NOT_YET_RECRUITING